机构：[1]Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing/ CN[2]Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu/CN四川大学华西医院[3]Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming/CN内科科室肿瘤放疗科肿瘤内科昆明医科大学附属第一医院[4]Department of Radiotherapy of the Chest and Abdomen, Affliated Tumor Hospital of Xinjiang Medical University, Urumqi/CN[5]Institute for Cancer Prevention and Treatment, Chongqing Sanxia Central Hospital, Chongqing/CN[6]Department of Medical Oncology, Xinqiao Hospital, Third Military Medical University, Chongqing/CN[7]Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing/CN[8]Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning/CN[9]Department of Radiotherapy, General Hospital of Ningxia Medical University, Yinchuan/CN[10]Department of Health Statistics, West China School of Public Health, Sichuan University, Chengdu/CN
第一作者机构：[1]Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing/ CN
推荐引用方式(GB/T 7714)：
Yang Z.,Zhang Y.,Li R.,et al.Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)[J].JOURNAL OF THORACIC ONCOLOGY.2018,13(10):S381-S382.doi:10.1016/j.jtho.2018.08.376.
APA：
Yang, Z.,Zhang, Y.,Li, R.,Yisikandaer, A.,Ren, B....&Zhang, J..(2018).Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER).JOURNAL OF THORACIC ONCOLOGY,13,(10)
MLA：
Yang, Z.,et al."Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)".JOURNAL OF THORACIC ONCOLOGY 13..10(2018):S381-S382
医学